Posted by Michael Wonder on 29 May 2017
CADTH publishes final recommendations for two Servier medicines
25 May 2017 - CADTH has published outcomes for edoxaban tosylate (Lixiana) and ivabradine hydrochloride (Lancora).
The CADTH Canadian Drug Expert Committee (CDEC) has recommended that edoxaban be reimbursed for the treatment of venous thromboembolism (deep vein thrombosis, pulmonary embolism) and the prevention of recurrent deep vein thrombosis and pulmonary embolism so long as there is a substantial reduction in price.
The CADTH CDEC has recommended that ivabradine hydrochloride be reimbursed for the treatment of stable chronic heart failure with reduced left ventricular ejection fraction (≤ 35%) in adult patients with New York Heart Association classes II or III who are in sinus rhythm with a resting heart rate ≥ 77 beats/minute, to reduce the incidence of cardiovascular mortality and hospitalisations for worsening heart failure, administered in combination with standard chronic heart failure therapies, if certain clinical criteria are met.
